SEC Form 4 · accession 0001562180-17-002011
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Ordentlich
Officer — Chief Scientific Officer
Period of report
May 17, 2017
Accepted (ET)
May 19, 2017 · 11:27 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 17, 2017 | M | 732 | $3.08 | A | 5,000 | D | |
| Common Stock | May 17, 2017 | S | 5,000 | $15.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $3.08 | May 17, 2017 | M | 732 | D | — | May 9, 2023 | Common Stock | 732 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
- F2The option is fully vested.